Jinyu Bio-Technology CoSHSE:600201 +2.93%68 Current Ratio is 3.66 as of Mar. 2026, which is 10% below its 10-year median of 4.07. GuruFocus rates SHSE:600201 with a GF Score™ of 68/100 and a GF Value™ of ¥8.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Jinyu Bio-Technology Co ranks worse than 52.3% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Jinyu Bio-Technology Co's current ratio for the quarter that ended in Mar. 2026 was 3.66.
Jinyu Bio-Technology Co has a current ratio of 3.66. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Jinyu Bio-Technology Co's Current Ratio or its related term are showing as below:
SHSE:600201'
s Current Ratio Range Over the Past 10 Years
Min: 2.79 Med: 4.07 Max: 7.59
Current: 3.66
During the past 13 years, Jinyu Bio-Technology Co's highest Current Ratio was 7.59. The lowest was 2.79. And the median was 4.07.
SHSE:600201's Current Ratio is ranked worse than 52.3% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs SHSE:600201: 3.66
Jinyu Bio-Technology Co (SHSE:600201) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jinyu Bio-Technology Co Current Ratio Related Terms
Jinyu Bio-Technology Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600201 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Jinyu Bio-Technology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinyu Bio-Technology Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Jinyu Bio-Technology Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinyu Bio-Technology Co (SHSE:600201) has a Current Ratio of 3.66 as of Mar. 2026. This is 10% below median its historical median of 4.07. Over the past decade, Jinyu Bio-Technology Co's Current Ratio has ranged from 2.79 to 7.59. According to the industry distribution chart, Jinyu Bio-Technology Co ranks #738 out of 1411 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Jinyu Bio-Technology Co's Current Ratio too high?
Jinyu Bio-Technology Co's current Current Ratio of 3.66 is 10% below median its 10-year median of 4.07. Over the past 10 years, this metric has ranged from a low of 2.79 to a high of 7.59. The Biotechnology industry median Current Ratio is 3.91. Jinyu Bio-Technology Co's value of 3.66 is 6.4% below this industry median. Based on the distribution chart, Jinyu Bio-Technology Co ranks #738 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jinyu Bio-Technology Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jinyu Bio-Technology Co ranks #738 out of 1411 companies for Current Ratio. This places Jinyu Bio-Technology Co in the lower half of its industry. The industry median Current Ratio is 3.91. Jinyu Bio-Technology Co's value of 3.66 is 6.4% below this benchmark. Historically, Jinyu Bio-Technology Co's own Current Ratio has ranged from 2.79 to 7.59 over the past decade. While the company's 10-year median is 4.07 vs. the industry median of 3.91, Jinyu Bio-Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinyu Bio-Technology Co's current Current Ratio of 3.66 is 6.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinyu Bio-Technology Co's current Current Ratio is 3.66, which is 10% below median its own 10-year median of 4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.23, compared to a current price of ¥12.31 — trading 49.6% above its estimated fair value. The current Current Ratio is 3.66, which is 10% below median its 10-year median of 4.07 and 6.4% below the Biotechnology industry median of 3.91. Jinyu Bio-Technology Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current Current Ratio is 3.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued.
The current stock price of ¥12.31 is trading 49.6% above its estimated GF Value™ of ¥8.23.
GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:600201:
Current Ratio: 3.66 (10% below median its 10-year median of 4.07)
GF Value™: ¥8.23 vs. price of ¥12.31 (49.6% above fair value)
Industry Position: 6.4% below the Biotechnology median (#738 of 1411)
No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
68GF Score
Get the complete analysis for SHSE:600201
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600201 has been successfully added to your 
